Institutional & Family Asset Management LLC Invests $31,000 in GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Institutional & Family Asset Management LLC acquired a new position in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 185 shares of the biopharmaceutical company’s stock, valued at approximately $31,000.

Several other institutional investors and hedge funds also recently modified their holdings of GWPH. Canada Pension Plan Investment Board increased its holdings in shares of GW Pharmaceuticals PLC- by 327.3% during the fourth quarter. Canada Pension Plan Investment Board now owns 1,175,000 shares of the biopharmaceutical company’s stock valued at $114,424,000 after acquiring an additional 900,000 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of GW Pharmaceuticals PLC- by 39.2% during the fourth quarter. Jennison Associates LLC now owns 515,281 shares of the biopharmaceutical company’s stock valued at $50,183,000 after acquiring an additional 145,227 shares in the last quarter. Federated Investors Inc. PA increased its holdings in shares of GW Pharmaceuticals PLC- by 23.5% during the first quarter. Federated Investors Inc. PA now owns 417,750 shares of the biopharmaceutical company’s stock valued at $70,420,000 after acquiring an additional 79,367 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of GW Pharmaceuticals PLC- by 80.4% during the first quarter. Victory Capital Management Inc. now owns 408,940 shares of the biopharmaceutical company’s stock valued at $68,935,000 after acquiring an additional 182,210 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in shares of GW Pharmaceuticals PLC- by 18.2% during the fourth quarter. Deutsche Bank AG now owns 270,575 shares of the biopharmaceutical company’s stock valued at $26,350,000 after acquiring an additional 41,593 shares in the last quarter. Institutional investors own 78.91% of the company’s stock.

Several equities research analysts have recently commented on the company. CIBC upgraded GW Pharmaceuticals PLC- from a “market perform” rating to an “outperform” rating in a report on Tuesday, May 7th. BidaskClub raised GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research report on Thursday, May 9th. Oppenheimer cut GW Pharmaceuticals PLC- from an “outperform” rating to a “market perform” rating and set a $195.00 target price on the stock. in a research report on Wednesday, May 8th. Guggenheim reaffirmed a “buy” rating and set a $222.00 target price (up previously from $186.00) on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, May 7th. Finally, JPMorgan Chase & Co. raised GW Pharmaceuticals PLC- from a “market perform” rating to an “outperform” rating in a research report on Wednesday, May 8th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the stock. GW Pharmaceuticals PLC- has a consensus rating of “Buy” and an average target price of $205.40.

GWPH stock traded up $0.25 during midday trading on Monday, hitting $172.64. The company’s stock had a trading volume of 289,200 shares, compared to its average volume of 439,678. The company’s 50-day moving average is $176.22. The company has a current ratio of 7.81, a quick ratio of 7.19 and a debt-to-equity ratio of 0.03. GW Pharmaceuticals PLC- has a 1 year low of $90.14 and a 1 year high of $196.00. The stock has a market cap of $5.20 billion, a PE ratio of -16.43 and a beta of 2.32.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($1.68) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.48) by $0.80. GW Pharmaceuticals PLC- had a negative return on equity of 45.75% and a negative net margin of 458.79%. The business had revenue of $39.20 million for the quarter, compared to analysts’ expectations of $12.32 million. During the same quarter in the previous year, the firm earned ($3.12) earnings per share. The business’s revenue was up 1189.5% on a year-over-year basis. Research analysts expect that GW Pharmaceuticals PLC- will post -4.76 earnings per share for the current year.

In other GW Pharmaceuticals PLC- news, insider Adam D. George sold 258,324 shares of the business’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $16.10, for a total value of $4,159,016.40. Following the sale, the insider now directly owns 268,324 shares in the company, valued at $4,320,016.40. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Justin D. Gover sold 202,224 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $15.24, for a total value of $3,081,893.76. Following the completion of the sale, the chief executive officer now owns 743,765 shares in the company, valued at $11,334,978.60. The disclosure for this sale can be found here. In the last three months, insiders sold 1,498,176 shares of company stock worth $22,921,432. Insiders own 5.50% of the company’s stock.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Further Reading: How is the discount rate different from the Federal Funds rate?

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.